Oslo, 4 July

Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 1 July 2025, regarding the board of directors' resolution to increase the share capital of the Company by the issuance of 6,000,000 new shares to Jiangsu Hongxin Medical Technology Co. Ltd ("Jiangsu") in connection with the private placement, at a subscription price of NOK 0.50 per share (the "Jiangsu Conversion Shares") through set-off against a receivable amounting to NOK 3,000,000 that Jiangsu had against the Company (following transfer of said receivable from Observe Medical AB to the Company pursuant to a debt transfer agreement dated 27 June 2025).

The share capital increase pertaining to the issuance of the Jiangsu Conversion Shares has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital is NOK 10,608,533.04, divided into 25,258,412 shares, each with a nominal value of NOK 0.42.

The Jiangsu Conversion Shares will be registered with the Norwegian Central Securities Depository Euronext Securities Oslo (the "VPS") on a separate ISIN from the existing shares of the Company, pending approval and publication by the Company of a prospectus (the "Prospectus") and will thus not be tradable on Euronext Expand Oslo until the Prospectus has been approved by the Financial Supervisory Authority of Norway (the "NFSA") and published by the Company, upon which the Jiangsu Conversion Shares will be transferred to the Company's ordinary ISIN in the VPS and be admitted to trading on Euronext Expand Oslo. The Prospectus is expected to be approved by the NFSA and published by the Company at the end of Q3 2025.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialisation of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.